Genome sequence of Corynebacterium pseudotuberculosis biovar equi strain 258 and prediction of antigenic targets to improve biotechnological vaccine production.

The research article is about the complete genome sequencing of Corynebacterium pseudotuberculosis biovar equi strain 258. The goal was to understand its genetic structure and identify potential antigenic proteins for better vaccine production to combat several veterinary diseases.

Introduction and Background

• The bacteria Corynebacterium pseudotuberculosis is responsible for several diseases in various animals, impacting economic sectors that rely on these animals. Its effects can differ based on the strain. For instance, the biovar ovis strain can cause caseous lymphadenitis in sheep and goats, while the biovar equi strain can lead to ulcerative lymphangitis in cows and horses.
• Existing vaccines targeting C. pseudotuberculosis primarily protect small ruminants such as sheep and goats. Additionally, these vaccines have significant shortcomings.

Genome Sequencing and Analysis

• This study presented a full genome sequence of C. pseudotuberculosis biovar equi strain 258, which was obtained from a horse suffering from ulcerative lymphangitis. The genome’s total size was found to be 2,314,404 bp, with 2088 forecasted protein-coding regions.
• The genome was further examined using in silico (computer-based) analysis. This analysis identified 11 regions, termed “pathogenicity islands”. These are genomic areas associated with virulence in bacteria and are crucial for the bacteria’s ability to cause disease.

Application to Vaccine Development

• Upon an in-depth analysis of the sequenced genome, the research identified 49 potentially antigenic proteins that could be used as candidates for vaccine targets.
• The application of reverse vaccinology was essential in this process – a method where the genomes of pathogenic organisms are analyzed to identify novel vaccine candidates.
• This identification of potential targets is a critical step forward in developing improved vaccines against the diseases caused by C. pseudotuberculosis and can serve as a foundation for more detailed experimental studies.